JP2013138681A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013138681A5 JP2013138681A5 JP2013048777A JP2013048777A JP2013138681A5 JP 2013138681 A5 JP2013138681 A5 JP 2013138681A5 JP 2013048777 A JP2013048777 A JP 2013048777A JP 2013048777 A JP2013048777 A JP 2013048777A JP 2013138681 A5 JP2013138681 A5 JP 2013138681A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- stranded rna
- region
- rna nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 11
- 230000001629 suppression Effects 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 239000004721 Polyphenylene oxide Substances 0.000 claims 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 230000009368 gene silencing by RNA Effects 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 229920000570 polyether Polymers 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 101150112014 Gapdh gene Proteins 0.000 description 8
- 0 CC(C)C(C)(CCC(C)C(C)O**)CCN1C(COC)CCC1 Chemical compound CC(C)C(C)(CCC(C)C(C)O**)CCN1C(COC)CCC1 0.000 description 7
- 238000010586 diagram Methods 0.000 description 5
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 101150077556 LMNA gene Proteins 0.000 description 1
- 101100127662 Mus musculus Lama1 gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- -1 sulfur-substituted monophosphate Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013048777A JP5555346B2 (ja) | 2010-08-03 | 2013-03-12 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010174915 | 2010-08-03 | ||
| JP2010174915 | 2010-08-03 | ||
| JP2010230806 | 2010-10-13 | ||
| JP2010230806 | 2010-10-13 | ||
| JP2010269823 | 2010-12-02 | ||
| JP2010269823 | 2010-12-02 | ||
| JP2011152381 | 2011-07-08 | ||
| JP2011152381 | 2011-07-08 | ||
| JP2013048777A JP5555346B2 (ja) | 2010-08-03 | 2013-03-12 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012026878A Division JP5261677B2 (ja) | 2010-08-03 | 2012-02-10 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013138681A JP2013138681A (ja) | 2013-07-18 |
| JP2013138681A5 true JP2013138681A5 (https=) | 2013-08-29 |
| JP5555346B2 JP5555346B2 (ja) | 2014-07-23 |
Family
ID=45559420
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537085A Expired - Fee Related JP4965745B2 (ja) | 2010-08-03 | 2011-07-28 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
| JP2012026878A Expired - Fee Related JP5261677B2 (ja) | 2010-08-03 | 2012-02-10 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
| JP2013048777A Expired - Fee Related JP5555346B2 (ja) | 2010-08-03 | 2013-03-12 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537085A Expired - Fee Related JP4965745B2 (ja) | 2010-08-03 | 2011-07-28 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
| JP2012026878A Expired - Fee Related JP5261677B2 (ja) | 2010-08-03 | 2012-02-10 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
Country Status (9)
| Country | Link |
|---|---|
| EP (4) | EP2628801B1 (https=) |
| JP (3) | JP4965745B2 (https=) |
| KR (3) | KR101894701B1 (https=) |
| CN (3) | CN103052711B (https=) |
| DK (1) | DK2674494T3 (https=) |
| ES (4) | ES2527660T3 (https=) |
| PT (1) | PT2674494E (https=) |
| TW (2) | TWI515294B (https=) |
| WO (1) | WO2012017919A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691782B2 (en) | 2010-08-03 | 2014-04-08 | Bonac Corporation | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton |
| WO2013077446A1 (ja) * | 2011-11-26 | 2013-05-30 | 株式会社ボナック | 遺伝子発現制御のための一本鎖核酸分子 |
| US9404108B2 (en) | 2012-03-04 | 2016-08-02 | Bonac Corporation | Micro-RMA inhibitor |
| WO2013133393A1 (ja) * | 2012-03-07 | 2013-09-12 | 学校法人東京医科大学 | Ｖｅｇｆ遺伝子の発現抑制用一本鎖核酸分子 |
| EP2832860A4 (en) * | 2012-03-29 | 2016-01-27 | Univ Kyushu Nat Univ Corp | NUCLEIC ACID MOLECULAR FOR INHIBITING EXPRESSION OF PERIOSTATING, METHOD FOR RESTRICTING THE EXPRESSION OF PERIOSTATING AND USE OF THE SAID NUCLEIC ACID MOLECULE |
| CN109810977A (zh) | 2012-05-26 | 2019-05-28 | 株式会社博纳克 | 具有递送功能的基因表达调控用单链核酸分子 |
| WO2015046451A1 (ja) * | 2013-09-27 | 2015-04-02 | 株式会社アクアセラピューティクス | 眼科疾患を除くペリオスチン発現に起因する疾患用医薬、およびその用途 |
| WO2015093495A1 (ja) * | 2013-12-16 | 2015-06-25 | 株式会社ボナック | ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子 |
| CN105899663B (zh) | 2013-12-26 | 2019-07-26 | 学校法人东京医科大学 | 用于基因表达控制的人工模拟miRNA及其用途 |
| SG10201913570XA (en) | 2013-12-27 | 2020-03-30 | Bonac Corp | Artificial match-type mirna for controlling gene expression and use therefor |
| JP6492014B2 (ja) * | 2013-12-27 | 2019-03-27 | 株式会社ボナック | 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途 |
| JP6726105B2 (ja) * | 2014-12-15 | 2020-07-22 | 株式会社ボナック | ＴＧＦ−β１発現抑制のための一本鎖核酸分子 |
| SG11201705223XA (en) * | 2014-12-27 | 2017-07-28 | Bonac Corp | NATURALLY OCCURING miRNA FOR CONTROLLING GENE EXPRESSION, AND USE OF SAME |
| JP6602847B2 (ja) | 2015-03-27 | 2019-11-06 | 株式会社ボナック | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 |
| JPWO2016167366A1 (ja) * | 2015-04-17 | 2018-04-05 | 国立大学法人 東京大学 | 眼疾患治療剤 |
| MX2018005146A (es) * | 2015-10-30 | 2018-08-23 | Bonac Corp | Composicion que contiene de manera estable molecula de acido nucleico de un solo filamento que suprime la expresion de gen tgf-b1. |
| CN108473988A (zh) * | 2015-12-29 | 2018-08-31 | 国立大学法人北海道大学 | 抑制肾素原基因或肾素原受体基因表达的单链核酸分子及其用途 |
| WO2017131124A1 (ja) * | 2016-01-26 | 2017-08-03 | 日産化学工業株式会社 | 一本鎖オリゴヌクレオチド |
| US11518994B2 (en) | 2016-01-30 | 2022-12-06 | Bonac Corporation | Artificial single guide RNA and use thereof |
| JP6787398B2 (ja) * | 2016-04-26 | 2020-11-18 | 住友化学株式会社 | 一本鎖核酸分子用モノマーの製造方法 |
| CN110337495B (zh) | 2017-02-06 | 2024-03-29 | 日产化学株式会社 | 单链寡核苷酸 |
| EP3604528A4 (en) | 2017-03-31 | 2021-01-13 | Bonac Corporation | CYCLIC NUCLEIC ACID MOLECULE WITH GENE EXPRESSION CONTROL FUNCTION |
| JPWO2018199338A1 (ja) * | 2017-04-27 | 2020-03-12 | 国立大学法人広島大学 | Ｂ型肝炎治療用核酸分子 |
| JP7204649B2 (ja) | 2017-07-28 | 2023-01-16 | 杏林製薬株式会社 | 線維症治療剤 |
| US20210188895A1 (en) * | 2017-10-13 | 2021-06-24 | Bonac Corporation | Single-stranded nucleic acid molecule, and production method therefor |
| TWI830718B (zh) | 2018-02-09 | 2024-02-01 | 日商住友化學股份有限公司 | 核酸分子之製造方法 |
| MX2020009765A (es) | 2018-03-20 | 2021-01-08 | Tokyo Inst Tech | Oligonucleotido antisentido reducido en toxicidad. |
| CN111819280A (zh) | 2018-03-30 | 2020-10-23 | 东丽株式会社 | 发夹型单链rna分子的制备方法 |
| EP3778914A4 (en) * | 2018-03-30 | 2022-01-19 | Sumitomo Chemical Company, Ltd. | Method for producing single-strand rna |
| TWI848981B (zh) * | 2018-10-02 | 2024-07-21 | 日商東麗股份有限公司 | 新穎亞磷醯胺、及髮夾型單股ｒｎａ分子之製造方法 |
| JP7241098B2 (ja) | 2019-01-25 | 2023-03-16 | 杏林製薬株式会社 | 線維症治療剤 |
| US12378275B2 (en) | 2019-03-29 | 2025-08-05 | Sumitomo Chemical Company, Limited | Porous inorganic carrier and method for producing nucleic acid using same |
| JP7510919B2 (ja) | 2019-03-29 | 2024-07-04 | 住友化学株式会社 | 無機多孔質担体及びこれを用いた核酸の製造方法 |
| WO2020202953A1 (ja) | 2019-03-29 | 2020-10-08 | 住友化学株式会社 | 無機多孔質担体、及びこれを用いた核酸の製造方法 |
| US12377409B2 (en) | 2019-03-29 | 2025-08-05 | Sumitomo Chemical Company, Limited | Inorganic porous carrier, and production method for nucleic acid using same |
| WO2020202949A1 (ja) | 2019-03-29 | 2020-10-08 | 住友化学株式会社 | Ｒｎａの製造方法 |
| US12509483B2 (en) | 2019-10-11 | 2025-12-30 | Sumitomo Chemical Company, Limited | Method for producing nucleic acid oligomers |
| US20230312635A1 (en) | 2020-01-29 | 2023-10-05 | Sumitomo Chemical Company, Limited | Method for producing nucleic acid oligomer |
| WO2021153770A1 (en) | 2020-01-29 | 2021-08-05 | Sumitomo Chemical Company, Limited | Process of preparing nucleic acid oligomer |
| US12522629B2 (en) | 2020-03-27 | 2026-01-13 | Sumitomo Chemical Company, Limited | Method for producing nucleic acid oligomer |
| KR102925978B1 (ko) | 2020-05-13 | 2026-02-10 | 스미또모 가가꾸 가부시끼가이샤 | 무기 다공질 기재, 무기 다공질 담체, 및 핵산의 제조 방법 |
| US20230242570A1 (en) | 2020-07-09 | 2023-08-03 | Sumitomo Chemical Company, Limited | Method for producing nucleic acid oligomer |
| JP7719788B2 (ja) * | 2020-09-24 | 2025-08-06 | 住友化学株式会社 | 核酸オリゴマーの製造方法 |
| KR20240082343A (ko) | 2021-09-28 | 2024-06-10 | 스미또모 가가꾸 가부시끼가이샤 | 정제 디클로로아세트산의 제조 방법 |
| KR20240162536A (ko) | 2022-03-23 | 2024-11-15 | 스미또모 가가꾸 가부시끼가이샤 | 핵산 올리고머의 제조 방법 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| GB9621367D0 (en) * | 1996-10-14 | 1996-12-04 | Isis Innovation | Chiral peptide nucleic acids |
| US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
| WO2005019453A2 (en) * | 2001-05-18 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| US6962906B2 (en) * | 2000-03-14 | 2005-11-08 | Active Motif | Oligonucleotide analogues, methods of synthesis and methods of use |
| TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
| AU2003219900A1 (en) * | 2002-02-22 | 2003-09-09 | James R. Eshleman | Antigene locks and therapeutic uses thereof |
| AU2003256857A1 (en) | 2002-08-08 | 2004-02-25 | Dharmacon, Inc. | Short interfering rnas having a hairpin structure containing a non-nucleotide loop |
| NL1022811C2 (nl) * | 2003-02-28 | 2004-08-31 | Fountain Patents B V | Systeem en werkwijze voor opslag en transport van zeecontainers. |
| AU2004227414A1 (en) * | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | iRNA conjugates |
| CA2538215A1 (en) * | 2003-09-30 | 2005-04-07 | Anges Mg, Inc. | Staple oligonucleotides and medicaments comprising the same |
| CA2572151A1 (en) * | 2004-06-30 | 2006-08-24 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a non-phosphate backbone linkage |
| WO2006074108A2 (en) * | 2004-12-30 | 2006-07-13 | Hauser Todd M | Compositions and methods for modulating gene expression using self-protected oligonucleotides |
| PL2129680T3 (pl) * | 2007-03-21 | 2015-10-30 | Brookhaven Science Ass Llc | Łączone kompozycje cząsteczek antysensownych o strukturze spinki do włosów oraz sposoby modulacji ekspresji |
| CN101889087B (zh) * | 2007-11-29 | 2013-04-03 | 苏州瑞博生物技术有限公司 | 一种干扰靶基因表达的复合分子及其制备方法 |
| WO2009082607A2 (en) * | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| WO2009076321A2 (en) * | 2007-12-07 | 2009-06-18 | Halo-Bio Rnai Therapeutics Inc. | Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides |
| JP2010174915A (ja) | 2009-01-27 | 2010-08-12 | Toyota Motor Corp | 高圧ガスタンク |
| JP5449815B2 (ja) | 2009-03-26 | 2014-03-19 | 住友化学株式会社 | 偏光板の製造方法 |
| JP2010269823A (ja) | 2009-05-21 | 2010-12-02 | British American Tobacco Japan Kk | 喫煙品用容器 |
| JP2011152381A (ja) | 2010-01-25 | 2011-08-11 | Ucom:Kk | 箸置き |
-
2011
- 2011-07-28 ES ES13184178.5T patent/ES2527660T3/es active Active
- 2011-07-28 DK DK13184178.5T patent/DK2674494T3/en active
- 2011-07-28 EP EP13167536.5A patent/EP2628801B1/en not_active Not-in-force
- 2011-07-28 KR KR1020187010010A patent/KR101894701B1/ko active Active
- 2011-07-28 PT PT131841785T patent/PT2674494E/pt unknown
- 2011-07-28 ES ES13167536.5T patent/ES2528285T3/es active Active
- 2011-07-28 EP EP13167541.5A patent/EP2639307B1/en active Active
- 2011-07-28 CN CN201180037592.9A patent/CN103052711B/zh not_active Expired - Fee Related
- 2011-07-28 KR KR1020137004646A patent/KR101849801B1/ko not_active Expired - Fee Related
- 2011-07-28 CN CN201410217512.3A patent/CN104059911B/zh not_active Expired - Fee Related
- 2011-07-28 ES ES11748250.5T patent/ES2443346T3/es active Active
- 2011-07-28 ES ES13167541.5T patent/ES2533129T3/es active Active
- 2011-07-28 JP JP2011537085A patent/JP4965745B2/ja not_active Expired - Fee Related
- 2011-07-28 EP EP13184178.5A patent/EP2674494B1/en active Active
- 2011-07-28 WO PCT/JP2011/067292 patent/WO2012017919A1/ja not_active Ceased
- 2011-07-28 KR KR1020187010011A patent/KR101894702B1/ko not_active Expired - Fee Related
- 2011-07-28 CN CN201410217071.7A patent/CN104004018B/zh not_active Expired - Fee Related
- 2011-07-28 EP EP11748250.5A patent/EP2436767B1/en active Active
- 2011-08-02 TW TW100127384A patent/TWI515294B/zh not_active IP Right Cessation
- 2011-08-02 TW TW104132132A patent/TWI572716B/zh not_active IP Right Cessation
-
2012
- 2012-02-10 JP JP2012026878A patent/JP5261677B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-12 JP JP2013048777A patent/JP5555346B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013138681A5 (https=) | ||
| RU2016142510A (ru) | Соединения и способы для транс-мембранной доставки молекул | |
| JP4968811B2 (ja) | 遺伝子発現制御のための一本鎖核酸分子 | |
| JP5555346B2 (ja) | 含窒素脂環式骨格を有する一本鎖核酸分子 | |
| AU2013289880B2 (en) | Chiral control | |
| JP2011092201A5 (https=) | ||
| JP6883349B2 (ja) | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 | |
| WO2015093495A1 (ja) | ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子 | |
| JP2020503049A5 (https=) | ||
| JP2010538677A5 (https=) | ||
| JP2009504783A5 (https=) | ||
| JP2016523087A5 (https=) | ||
| JP2021520387A (ja) | Ｂ型肝炎ウイルス感染を治療するためのｆｕｂｐ１阻害剤の使用 | |
| JP2021502346A5 (https=) | ||
| JP2013506720A5 (https=) | ||
| JP6283859B2 (ja) | ペリオスチン遺伝子の発現抑制核酸分子、ペリオスチン遺伝子の発現抑制方法、およびその用途 | |
| JP2013513632A5 (https=) | ||
| WO2015099188A1 (ja) | 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途 | |
| JPWO2015046451A1 (ja) | 眼科疾患を除くペリオスチン発現に起因する疾患用医薬、およびその用途 | |
| JP2009522281A5 (https=) | ||
| WO2016098782A1 (ja) | ＴＧＦ－β１発現抑制のための一本鎖核酸分子 | |
| RU2020118025A (ru) | Нуклеиновая кислота, композиция и конъюгат, содержащие ее, а также способ их получения и применения |